Baseline patient characteristics
| Characteristic | No of patients (%, N=76) |
| Age, median (range) | 67 (25–92) |
| Male sex | 50 (66) |
| Cancer type | |
| Melanoma | 62 (82) |
| Lung | 5 (7) |
| Head and neck cancer | 2 (3) |
| Esophageal adenocarcinoma | 2 (3) |
| Other | 5 (7) |
| Cancer stage | |
| III | 21 (28) |
| Adjuvant/neoadjuvant | 9 (12) |
| Non-adjuvant | 12 (16) |
| IV | 55 (72) |
| Adjuvant | 1 (1) |
| Non-adjuvant | 54 (71) |
| Immunotherapy class | |
| Anti-PD-1/PD-L1 | 51 (67) |
| Anti-CTLA-4 | 8 (11) |
| Combination PD-1/CTLA-4 blockade | 17 (22) |
| Type of psoriasis | |
| Plaque | 46 (61) |
| Guttate* | 4 (5) |
| Pustular | 2 (3) |
| Psoriatic arthritis only | 3 (4) |
| Not specified/unknown | 21 (28) |
| Psoriatic arthritis | 15 (20) |
| Median duration of psoriasis symptoms, years (range) | 9 (1 month–54 years) |
| Other extracutaneous disease associations (including uveitis/iritis, IBD, CVD) | 10 (13) |
| Prior psoriasis therapy | |
| Acitretin | 1 (1) |
| Biologics† | 3 (4) |
| Methotrexate‡ | 6 (8) |
| Prednisone | 1 (1) |
| Small molecule inhibitors | 3 (4) |
| Topical therapy only | 27 (36) |
| None | 35 (46) |
| Active immunosuppressant psoriasis therapy at start of immunotherapy | 2 (3) |
| Other pre-existing autoimmune disease | 6 (8) |
Biologics include adalimumab and etanercept. Small molecule inhibitors include tofacitinib and apremilast.
*Includes two patients with guttate and plaque psoriasis.
†One patient on acitretin.
‡One patient on prednisone.
CVD, cardiovascular disease; IBD, inflammatory bowel disease.